CliffBio
small molecule

BENICAR HCT

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

Loss of exclusivity—loss of exclusivity
CompanyCosette Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameBENICAR HCT
Active ingredientHYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
Strength25MG;40MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJune 2003
Marketing statusRX

More from Cosette Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.